Gastroesophageal junction adenocarcinoma

Related records

Broader conditions (16)

• Adenocarcinoma
• Cancer
• Cancer or benign tumor
• Carcinoma
• Digestive system cancer
• Digestive system carcinoma
• Digestive system disorder
• Digestive system neoplasm
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Epithelial neoplasm
• Glandular cell neoplasm
• Human disease
• Neoplasm
• Neoplastic disease or syndrome

Trials (375)

• 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
• A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma
• A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
• A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab
• A Multicenter Cancer Biospecimen Collection Study
• A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
• A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
• A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
• A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
• A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
• A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
• A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
• A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
• A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
• A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG
• A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
• A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
• A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
• A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

Approved drugs (4)

• Docetaxel
• Fluorouracil
• Tislelizumab
• Zolbetuximab

Drugs in development (51)

• Adebrelimab Phase 2
• Albumin human Phase 2
• AMG-337 Phase 1
• Atezolizumab Phase 1
• Bevacizumab Phase 2
• Cadonilimab Phase 3
• Camrelizumab Phase 2
• Cantuzumab ravtansine Phase 2
• Capecitabine Phase 3
• Carboplatin Phase 2
• Cisplatin Phase 3
• Cobimetinib Phase 1
• Cyclophosphamide Phase 3
• Envafolimab Phase 2
• Epirubicin Phase 2
• Fexagratinib Phase 2
• Fludarabine Phase 1
• Fruquintinib Phase 1
• Ganetespib Phase 1
• Gemcitabine Phase 2